What moved in your trials overnight.

Pick a sponsor or disease. Every morning DataLookout compares each of their ClinicalTrials.gov records with yesterday's and sends you the differences: status, dates, enrollment, endpoints, sites, and the reason a trial stopped.

Free plan is free for good: one sponsor, one disease, no card. Paid plans from $49/month.

From the sweep of 14 November 2026668 changes on 348 trials
2026-11-14
critical
Withdrawn before enrolling
Trial withdrawn: An alternative study design is under consideration.
NCT07638566 A Study to Assess the Correct Dose, Safety and Efficacy of… · argenx · Phase 2/3
2026-11-14
critical
Trial terminated
Trial terminated: BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibility and the...
Final enrollment: 18 participants (planned 30)
Primary completion date changed from estimate of Mar 2027 to Sep 16, 2026
NCT06668805 A Study of Vosoritide in Children With Noonan Syndrome With… · BioMarin Pharmaceutical · Phase 2
2026-11-13
notable
Enrollment reduced: 1276 → 784 participants
Primary completion pushed from Jan 31, 2027 to Jan 31, 2029
Study completion pushed from Apr 30, 2027 to Jun 30, 2029
Interventions modified
NCT05139849 VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest… · Tiohundra AB · Phase 3
2026-11-13
notable
Primary endpoint(s) modified
Results posted: Nov 12, 2026
NCT04963296 A Study to Evaluate the Efficacy and Safety of Obinutuzumab in… · Hoffmann-La Roche · Phase 3
2026-11-13
notable
Primary endpoint(s) modified
Recruitment opened
Enrollment increased: 200 → 326 participants
NCT07739199 A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific… · Sichuan Baili Pharmaceutical Co., Ltd. · Phase 2/3
2026-11-13
notable
Primary endpoint(s) modified
Enrollment reduced: 840 → 740 participants
Interventions modified
NCT06879145 Clinical Study on the Treatment of MIBC Patients With SHR-A2102… · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase 2/3
Six real entries from the seven days to 14 November 2026, exactly as detected. Every value is checkable on ClinicalTrials.gov by NCT number.

ClinicalTrials.gov keeps every version. Nobody has time to read them.

A registry record can change quietly: a completion date slides a year, an endpoint is reworded, a stopped trial gets its reason weeks later. The registry stores each version but shows you one trial at a time. DataLookout reads the versions for the sponsors and diseases you name and reports only what differs, with the old value next to the new one.

  • Overall statusrecruiting, suspended, terminated, completedThe change most people want first. Terminations and suspensions are marked critical.
  • Primary completion dateand study completion dateThe readout clock. A push of 30 days or more is flagged; the size of the shift is shown as a floor.
  • Enrollment countCuts often precede a termination. Increases usually mean an expansion.
  • Why the trial stoppedfree text from the sponsorQuoted verbatim, because it typically arrives after the status flips.
  • Primary endpointsRewrites are flagged, not interpreted. You read the before and after.
  • Phase, arms, sites, sponsorand new trials registeredPhase moves, arm and site counts, a change of lead sponsor, and any new record from a sponsor you watch or in a disease you watch.
The DataLookout record page for NCT06149286: title, status, the At Risk flag, and the Record History with what moved in each version
The record page for one trial on dashboard.datalookout.com, captured 18 August 2026. Every value is the registry's, with the version it changed in.
Trials at Risk

The ones slipping while still marked "Recruiting."

A trial rarely announces trouble. It pushes its date, trims enrollment, and rewrites an endpoint, each edit small enough to pass. Trials at Risk collects those signals across your watchlist and ranks the trials that show more than one.

Full list on Pro. Free shows the top 2 trials.

2026-08-15
notable
Primary completion pushed 27 months: 2029-01-23→2031-04-30
NCT06149286 Regeneron Pharmaceuticals · Phase 3 · odronextamab + lenalidomide · follicular lymphoma
2026-08-15
minor
Primary endpoints rewritten in the same update
2026-08-15
minor
Enrollment raised 470→580
2026-08-15
minor
Status unchanged: Recruiting
Three signals in one registry update, detected 15 August 2026. Still recruiting on the record.

How it works

Three steps, then it runs without you. Everything is drawn from ClinicalTrials.gov's official API, unmodified.

  1. Name a sponsor or diseaseSearch 150,000+ trials by sponsor, condition, or NCT number. Add what matters to your watchlist, or save any search (a phase, a status, a start-date window) and get a daily or weekly digest when its results change. Adding a company turns your watchlist into a running drug pipeline tracker for the trials it has active.
  2. We compare, every morningEach watched record is diffed against yesterday's version across the fields above. Each change is marked Stopped, Notable or Minor. That is automated clinical trial monitoring, and it runs whether or not you log in.
  3. You read the differencesA daily or weekly email covering your watchlist and saved searches, plus a dashboard where each change can be marked read or done, with the change history, a landscape analysis of every sponsor active in a disease, and Trials at Risk.

Pricing

Start free, no card. Cancel any time from your account page.

Free$0 forever Pro$49 / month, or $490 / year
Watchlist1 sponsor + 1 disease10 sponsors + 10 diseases
Saved searches in your email digest110
Tracked individual trials525
Daily change detectionYesYes
Email digest (watchlist + saved searches)Daily or weeklyDaily or weekly
Trials at RiskTop trial onlyFull list
Completions calendarPreviewFull
Landscape reportsPreviewFull
Pipeline PulseYesYes
CSV export—Yes
Support—Email
Start free Sign up for Pro

Search and browse 150,000+ trials on every plan. Prices in USD, billed monthly or yearly.

FAQ

Frequently asked questions

Is the free plan really free?
Yes. The free plan is free forever. You get 1 sponsor and 1 disease watchlist with full change detection, and you can search and browse 150,000+ trials with no time limit. Upgrade to Pro when you want more.
How is this different from searching ClinicalTrials.gov directly?
ClinicalTrials.gov keeps a full version history for every trial and offers RSS feeds for new and updated studies. What it does not do is compare versions across a set of sponsors or diseases and tell you which field moved and from what value. DataLookout does that comparison for your watchlist every morning.
What is change detection?
DataLookout takes daily snapshots of the trials it tracks and compares fourteen fields on each one. When a trial changes status, advances phase, updates enrollment, moves a completion date, modifies a primary endpoint, changes its interventions, adds sites, gains a stated reason for stopping, or publishes its results, the change is recorded with the old and new value and marked Stopped, Notable or Minor.
What is Trials at Risk?
Trials at Risk flags the active trials on your watchlist showing warning signs: a primary completion date pushed out by 30 or more days, enrollment cut, or a primary endpoint changed. Trials with several signals rank highest. Free accounts see the top trial; Pro sees the full list.
Will I be notified about new trials, not just changes?
Yes. When a sponsor on your watchlist registers a new trial on ClinicalTrials.gov, or a new sponsor appears in a disease you watch, it appears in your next email digest as a New Trial entry, separate from changes to existing trials.
What are Landscape Reports and Pipeline Pulse?
A Landscape Report is a full breakdown of a disease area: the most active sponsors grouped by phase, a phase distribution chart, recent protocol changes, and new entrants. Pipeline Pulse ranks 88 disease areas by trial momentum, a composite of Phase 3 density, new starts, and new sponsor entrants.

Name one sponsor or disease. Read tomorrow's differences.

Free forever for one of each. No card.

Start watching for free →